ZYME (Zymeworks) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZYME Zymeworks Inc ZYME
65 GF Score
Price $23.54
GF Value $15.58
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Zymeworks Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

ZYME
65GF Score
Zymeworks Inc ZYME
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zymeworks (ZYME) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of $23.54 is trading 51.1% above its estimated GF Value™ of $15.58. GuruFocus considers Zymeworks to be Significantly Overvalued.

Key valuation signals for ZYME:

  • Interest Expense (Positive):
  • GF Value™: $15.58 vs. price of $23.54 (51.1% above fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
65GF Score

Get the complete analysis for ZYME

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.54
Price
$15.58
GF Value